NASDAQ:CRON

Cronos Group (CRON) Stock Price, News & Analysis

$2.90
-0.03 (-1.02%)
(As of 05/15/2024 ET)
Today's Range
$2.89
$3.01
50-Day Range
$1.96
$2.94
52-Week Range
$1.64
$3.12
Volume
2.59 million shs
Average Volume
3.04 million shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Cronos Group MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
3.4% Upside
$3.00 Price Target
Short Interest
Healthy
3.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Cronos Group in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.10 out of 5 stars

Medical Sector

899th out of 928 stocks

Medicinals & Botanicals Industry

10th out of 10 stocks

CRON stock logo

About Cronos Group Stock (NASDAQ:CRON)

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

CRON Stock Price History

CRON Stock News Headlines

7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Cronos: Q1 Earnings Snapshot
Cronos Group Reports 2024 First Quarter Results
The 3 Best Meme Stocks to Buy in May 2024
Cronos Enters United Kingdom Cannabis Market
3 Cannabis Penny Stocks to Buy for 3-Bagger Returns
Why Marijuana Stocks Got Burnt Today
See More Headlines
Receive CRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cronos Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/15/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:CRON
Fax
N/A
Employees
356
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.50
Low Stock Price Target
$2.50
Potential Upside/Downside
-6.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
2 Analysts

Profitability

Net Income
$-73,960,000.00
Pretax Margin
-61.53%

Debt

Sales & Book Value

Annual Sales
$87.24 million
Book Value
$2.81 per share

Miscellaneous

Free Float
374,524,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
1.11
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

CRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Cronos Group stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CRON shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares.
View CRON analyst ratings
or view top-rated stocks.

What is Cronos Group's stock price target for 2024?

2 brokerages have issued 12 month target prices for Cronos Group's stock. Their CRON share price targets range from $2.50 to $3.50. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts price targets for CRON
or view top-rated stocks among Wall Street analysts.

How have CRON shares performed in 2024?

Cronos Group's stock was trading at $2.09 at the start of the year. Since then, CRON stock has increased by 38.8% and is now trading at $2.90.
View the best growth stocks for 2024 here
.

When is Cronos Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our CRON earnings forecast
.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). The firm earned $25.29 million during the quarter, compared to analyst estimates of $24.30 million. Cronos Group had a negative trailing twelve-month return on equity of 3.06% and a negative net margin of 61.31%. During the same period in the prior year, the company posted ($0.03) EPS.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include Tilray (TLRY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and Organigram (OGI).

Who are Cronos Group's major shareholders?

Cronos Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.86%), Mirae Asset Global Investments Co. Ltd. (0.26%), IMC Chicago LLC (0.00%), Janney Montgomery Scott LLC (0.08%), SeaCrest Wealth Management LLC (0.02%) and Madrona Financial Services LLC (0.01%).
View institutional ownership trends
.

How do I buy shares of Cronos Group?

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRON) was last updated on 5/15/2024 by MarketBeat.com Staff

From Our Partners